Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

/PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of...

Related Keywords

Houston ,Texas ,United States ,Singapore ,Amsterdam ,Noord Holland ,Netherlands ,Innovent Biologics ,Youtube ,Twitter ,Platform Technology ,Hummingbird Bioscience ,Hummingbird Bio ,Rational Antibody Discovery ,Chief Executive Officer ,Piers Ingram ,Mersana Therapeutics ,Shanghai Miracogen ,Kyowa Kirin ,Biogeneration Ventures ,